Medicine | Oncology
Prostate cancer
Prognosis
Prediction tools: PCA3 and other prostate antigens


Home > Disciplines > Medicine > Oncology > Prostate cancer > Prognosis > PCA3 and other prostate antigens


Prostate Cancer Antigen 3




PROGRESSION-FREE SURVIVAL


.

Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU.
Prostate Cancer Antigen 3 (PCA3) Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-Free Survival in Clinically-Localized, Intermediate- and High-Risk Prostate Cancer.
Urology. 2017 May 25. pii: S0090-4295(17)30565-4. doi: 10.1016/j.urology.2017.05.028. [Epub ahead of print]
Source | Full text | Similar articles



[-2]proPSA (p2PSA)




CANCER DETECTION


.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G, Lazzeri M.
Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
Korean J Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub 2014 Jul 11.
Source | Full text | Similar articles



.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.
Source | Full text | Similar articles



BIOCHEMICAL RECURRENCE


.

Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi N.
[-2]proPSA for predicting biochemical recurrence of prostate cancer earlier than total PSA after radical prostatectomy: an observational prospective cohort study.
Minerva Urol Nefrol. 2019 Jan 28. doi: 10.23736/S0393-2249.19.03279-X. [Epub ahead of print]
Source | Abstract | Similar articles



.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.
Source | Full text | Similar articles



.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.
Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.
Source | Full text | Similar articles



.

Huang YQ, Sun T, Zhong WD, Wu CL.
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.
Am J Clin Exp Urol. 2014 Dec 25;2(4):343-50. eCollection 2014.
Source | Full text | Similar articles



.

Lazzeri, M., Lughezzani, G., Larcher, A., Lista, G., Gadda, G. M., Scattoni, V., … Guazzoni, G.
Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead’s Letter to the Editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer. Eur Urol 2012;61:455–66. European Urology, 62(1), e16–e17.
Eur Urol. 2012 Jul;62(1):author reply e16-7. doi: 10.1016/j.eururo.2012.04.029. Epub 2012 Apr 17.
Source | Full text | Similar articles
Referring to: Tadtayev S et al, Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66. Eur Urol. 2012 Jul;62(1):e14-5; doi: 10.1016/j.eururo.2012.04.030. Epub 2012 Apr 17. Source , Full text
In turn referring to: Guazzoni G et al., Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.
Source , Full text



.

Tadtayev S, McNicholas TA, Boustead GB.
Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
Eur Urol. 2012 Jul;62(1):e14-5; author reply e16-7. doi: 10.1016/j.eururo.2012.04.030. Epub 2012 Apr 17.
Source | Full text | Similar articles
Referring to: Guazzoni G et al., Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.
Source , Full text